Pharmacogenomics: The Future of ADHD Treatment Options

 ADHD in the News 2019-12-12

Researchers from universities around the world conducted a meta-analysis of genome-wide association studies to explore genes that could be potential targets for pharmacologic therapy of Attention-Deficit Hyperactivity Disorder (ADHD), and its comorbidities. The comorbidities included in the study fell into 3 categories: cardiovascular, immune, and neuropsychiatric. The study results were published in the journal Molecular Psychiatry.